ReviewExperimental hematology & oncology2026
Methods and applications of patient-derived organoid models for immune microenvironment and immunotherapy research in multiple cancer types.
Review in Experimental hematology & oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lack of pre-clinical models that simulate the complex TME and translate to human immunity is list as the top one challenge in the area of cancer immunotherapy development. While newly emerging organoid models play a crucial role in promoting the development of precision medicine in cancer immunotherapies. With the aid of experimental techniques and co-culture models of immuno-oncology, researchers have made progress in modeling tumor microenvironment (TME) with organoid-immune co-culture technologies to enhance the cellular complexity of the in vitro models, thus helping to improve existing immunotherapies, identify new immunotherapies and find reliable markers to predict the efficacy of immunotherapies for patients with cancer. In the review, we present an overview of the development of the different methods of three-dimensional (3D) patient-derived tumor organoids (PDTOs) modeling TME to study the interaction of tumor with cancer-associated fibroblasts (CAFs), lymphoid cells and myeloid immune cells. Besides, their methods and application in screening for efficacy of pharmacological immunotherapy and cellular immunotherapy in a personalized manner have also been summarized in the review. Moreover, we describe the applications of PDTOs modeling TME in specific cancer types and then summarize their contributions to the development of tumor immunity in different types of cancers. By centering on PDTOs' ability to capture individual tumor-immune biology, the review offers a comprehensive, personalized perspective of PDTO-immune co-culture models, making it a critical resource for researchers, clinicians, and drug developers aiming to advance precision immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.